Arrivent Biopharma, Common Stock Performance
| AVBP Stock | 18.25 0.74 3.90% |
The firm shows a Beta (market volatility) of 1.29, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ArriVent BioPharma, will likely underperform. At this point, ArriVent BioPharma, has a negative expected return of -0.58%. Please make sure to confirm ArriVent BioPharma,'s jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if ArriVent BioPharma, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ArriVent BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (6.04) | Five Day Return (1.66) | Year To Date Return (30.87) | Ten Year Return (5.05) | All Time Return (5.05) |
1 | ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in 1.2B Deal - StockTitan | 01/21/2025 |
2 | HC Wainwright Issues Optimistic Forecast for AVBP Earnings | 01/24/2025 |
3 | ArriVent BioPharma Reports Full Year 2024 Financial Results | 03/03/2025 |
4 | Discretionary transaction by Orbimed Advisors Llc of 821827 shares of ArriVent BioPharma, subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 150.4 M |
ArriVent |
ArriVent BioPharma, Relative Risk vs. Return Landscape
If you would invest 2,758 in ArriVent BioPharma, Common on December 26, 2024 and sell it today you would lose (859.00) from holding ArriVent BioPharma, Common or give up 31.15% of portfolio value over 90 days. ArriVent BioPharma, Common is currently does not generate positive expected returns and assumes 2.9619% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than ArriVent, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ArriVent BioPharma, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ArriVent BioPharma,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ArriVent BioPharma, Common, and traders can use it to determine the average amount a ArriVent BioPharma,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1946
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AVBP |
Estimated Market Risk
| 2.96 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.58 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ArriVent BioPharma, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ArriVent BioPharma, by adding ArriVent BioPharma, to a well-diversified portfolio.
ArriVent BioPharma, Fundamentals Growth
ArriVent Stock prices reflect investors' perceptions of the future prospects and financial health of ArriVent BioPharma,, and ArriVent BioPharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ArriVent Stock performance.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 468.78 M | ||||
| Shares Outstanding | 34.02 M | ||||
| Price To Book | 2.67 X | ||||
| EBITDA | (74.59 M) | ||||
| Net Income | (80.49 M) | ||||
| Total Debt | 176 K | ||||
| Book Value Per Share | 7.64 X | ||||
| Cash Flow From Operations | (70.21 M) | ||||
| Earnings Per Share | (2.56) X | ||||
| Market Capitalization | 687.47 M | ||||
| Total Asset | 274.94 M | ||||
| Retained Earnings | (238.33 M) | ||||
| Working Capital | 209.71 M | ||||
About ArriVent BioPharma, Performance
Assessing ArriVent BioPharma,'s fundamental ratios provides investors with valuable insights into ArriVent BioPharma,'s financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ArriVent BioPharma, is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.57) | (0.59) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.41) | (0.43) |
Things to note about ArriVent BioPharma, performance evaluation
Checking the ongoing alerts about ArriVent BioPharma, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ArriVent BioPharma, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ArriVent BioPharma, generated a negative expected return over the last 90 days | |
| ArriVent BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (80.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ArriVent BioPharma, generates negative cash flow from operations | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: ArriVent BioPharma Reports Full Year 2024 Financial Results |
- Analyzing ArriVent BioPharma,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ArriVent BioPharma,'s stock is overvalued or undervalued compared to its peers.
- Examining ArriVent BioPharma,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ArriVent BioPharma,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of ArriVent BioPharma,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ArriVent BioPharma,'s stock. These opinions can provide insight into ArriVent BioPharma,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma,'s price analysis, check to measure ArriVent BioPharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma, is operating at the current time. Most of ArriVent BioPharma,'s value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma,'s price. Additionally, you may evaluate how the addition of ArriVent BioPharma, to your portfolios can decrease your overall portfolio volatility.